Peptide Sciences Shutdown: A Guide to Sourcing Verified Research Peptides

Understanding the Peptide Sciences Shutdown

What happened to Peptide Sciences? On March 6, 2026, Peptide Sciences, a long-standing supplier in the research chemical market, ceased all operations. The company posted a brief, three-sentence notice on their website before going offline permanently. This closure was abrupt, leaving many researchers without their established source for compounds such as BPC-157, TB-500, and various GLP-1 analogs. As reported by [adaptpeptides.com](https://adaptpeptides.com/peptide-sciences-shut-down/), the company provided no transition plan for customers or guidance on outstanding orders.

Why did the company close? The closure occurred at the intersection of three major industry pressures. According to analysis from [thepeptidecatalog.com](https://thepeptidecatalog.com/articles/peptide-sciences-shut-down-alternatives), the primary drivers included: * **Regulatory Enforcement:** Increased scrutiny from the FDA regarding the "research use only" (RUO) labeling model, which federal agencies have increasingly scrutinized as a potential loophole for distributing unapproved drugs. * **Pharmaceutical Litigation:** Major pharmaceutical companies, including Eli Lilly and Novo Nordisk, initiated legal actions to protect patents on GLP-1 compounds like semaglutide and tirzepatide. * **Quality Concerns:** Independent testing platforms, such as those cited by [peptideprotocolwiki.com](https://www.peptideprotocolwiki.com/blog/peptide-sciences-shut-down), identified significant inconsistencies in product purity, particularly regarding retatrutide, which failed to meet quality benchmarks in multiple independent analyses.

Navigating the Current Research Market

Is the "Research Use Only" model still viable? The scientific community continues to utilize synthetic peptides for preclinical and *in vitro* studies. However, the legal environment surrounding these compounds is in flux. As noted by [peptideprotocolwiki.com](https://www.peptideprotocolwiki.com/blog/peptide-sciences-shut-down), recent policy shifts—including potential reclassifications by federal health authorities—suggest that some peptides may soon become more accessible through regulated compounding pharmacies with a valid prescription, rather than through unregulated grey-market suppliers.

How can researchers verify peptide quality? Reliable sourcing now requires a higher standard of due diligence. When evaluating new suppliers, researchers should prioritize the following: * **Third-Party Certificates of Analysis (COA):** A trustworthy supplier must provide batch-specific testing results from an accredited, independent laboratory. Avoid vendors that use generic or outdated COAs. * **Transparency in Synthesis:** Suppliers should be able to disclose the method of synthesis and purification (e.g., HPLC or Mass Spectrometry verification). * **Regulatory Compliance:** Ensure the vendor adheres to current labeling requirements and operates with transparency regarding their supply chain.